Integral Diagnostics Allocates 67,226 Shares to CEO and CFO After Stage 2 Capital Merger Performance Rights Vest

Stage 2 Capital Merger Performance Incentive Triggers Share Issuance for IDX Executives

The 1 July 2026 share issuance represents the second phase of a structured executive incentive program directly linked to Integral Diagnostics’ Capital Merger integration. The 2025 Remuneration Report and 2025 AGM Notice of Meeting previously detailed the framework, under which performance rights vest in stages upon achieving specified merger-related milestones. The conversion of 67,226 IDXAF Short-Term Incentive (STI) performance rights into fully paid ordinary shares confirms that Stage 2 requirements have been met, although the company did not specify the exact performance metrics in this announcement.

The Capital Merger Performance Incentive was designed to reward senior Leadership for effectively integrating acquisitions and delivering measurable results tied to the merged entity’s performance. By structuring rewards across multiple stages, the board aimed to retain key executives and align management incentives with Shareholder value over time. Completion of Stage 2 marks a significant milestone in this incentive plan, with further stages potentially dependent on future performance outcomes.

CEO Dr Ian Kadish Awarded 37,678 Shares

Dr Ian Kadish, Integral Diagnostics’ Chief Executive Officer, received 37,678 fully paid ordinary shares as part of the Stage 2 vesting. These shares were registered in his name, as confirmed in the company’s update. Dr Kadish has played a pivotal role in steering the company’s strategic direction, including overseeing the integration of its expanded radiology network following the Capital Merger.

This share vesting increases Dr Kadish’s direct Equity stake in Integral Diagnostics, further aligning his financial interests with those of ordinary shareholders. Executive share ownership is often viewed positively by investors and governance experts, as it narrows the gap between management incentives and long-term shareholder returns. The company did not disclose Dr Kadish’s total shareholding after this issuance or provide commentary on his performance evaluation in this update.

CFO Craig White Converts 29,548 STI Performance Rights to Shares

Chief Financial Officer Mr Craig White, whose shares are registered under the name John Craig Uttermare White, received 29,548 fully paid ordinary shares from the conversion of IDXAF STI performance rights on 1 July 2026. Mr White is responsible for Integral Diagnostics’ financial management, capital allocation, and reporting across its growing network of imaging clinics in Australia and New Zealand.

The allocation of shares under the performance incentive plan reflects the board’s conclusion that both executives met the Stage 2 performance hurdles. Similar to Dr Kadish, the company did not disclose Mr White’s total shareholding following the conversion or elaborate on the specific financial or integration benchmarks evaluated for vesting.

Conversion Process of 67,226 IDXAF Performance Rights to Ordinary Shares on ASX

This conversion involved reclassifying unquoted IDXAF Short-Term Incentive performance rights into existing IDX ordinary fully paid shares, which are traded on the Australian Securities Exchange. Such conversions are standard corporate actions for ASX-listed companies operating employee incentive schemes: once performance conditions are met and rights vest, the underlying unquoted securities convert into a quoted security class—in this case, ordinary shares. The newly issued shares join the existing pool of IDX ordinary shares on the market.

Integral Diagnostics filed an Appendix 3G form with the ASX to notify the market of this conversion. This filing is mandated under ASX Listing Rules whenever unquoted securities like performance rights or Options are converted or exercised into quoted securities. The disclosure ensures transparency and enables the market to adjust for changes in total shares on issue, which impact metrics such as Earnings Per Share and dilution calculations relevant for equity valuation.

Total Ordinary Shares Increase to 373,066,537 Post-Vesting

After issuing the 67,226 new shares, Integral Diagnostics’ total quoted ordinary shares outstanding reached 373,066,537, as reported in Part 4 of the Appendix 3G filing. This figure reflects the company’s updated Issued Capital as of 1 July 2026, with the ASX noting that automated figures may not capture other simultaneous transactions.

Given the company’s share base exceeds 373 million, the addition of 67,226 shares represents a dilution of less than 0.02%, which analysts generally consider immaterial for existing shareholders. Nonetheless, the conversion is significant from a governance and remuneration transparency perspective because it confirms that milestone-based executive incentives have been achieved and that senior leaders are rewarded with equity rather than cash, preserving company Liquidity.

Outstanding Unquoted Securities at IDX Include Over 3.8 Million Performance Rights and Options

Following the Stage 2 conversion, Integral Diagnostics still holds a range of unquoted securities within its Capital Structure. The Appendix 3G filing lists 907,990 unquoted options expiring at various dates and exercisable at different prices (IDXAB), 2,444,653 Long-Term Incentive performance rights (IDXAA), and 505,553 STI performance rights (IDXAF) outstanding. These figures reflect the position after the 67,226 share issuance and illustrate the ongoing scope of the company’s executive incentive framework.

The remaining 505,553 IDXAF STI performance rights indicate that further vesting events may occur in future periods if performance conditions are met. Likewise, the 2,444,653 LTI performance rights under IDXAA represent a longer-term incentive pool that may convert to ordinary shares over several years, contingent on Integral Diagnostics meeting its long-term strategic and financial objectives. Investors monitoring dilution risk and executive remuneration should closely follow announcements related to these securities.

Overview of the Capital Merger Performance Incentive and Its Disclosure in 2025 Reports

The Capital Merger Performance Incentive was created specifically to support executive remuneration linked to Integral Diagnostics’ major merger activities. The company stated that full terms of this incentive were disclosed in the 2025 Remuneration Report and the 2025 Annual General Meeting Notice of Meeting, both accessible to shareholders prior to the AGM vote. Such incentive structures are typically subject to shareholder review under ASX Listing Rule requirements governing employee incentive schemes involving key management personnel.

Stage-based incentives like this are designed to ensure executives earn payouts progressively rather than in a lump sum, mitigating the risk of rewarding short-term decisions without sustained integration success. Completion of Stage 2 indicates the plan is advancing as intended. However, investors seeking detailed information on total potential incentive value, remaining stages, or specific hurdle rates should consult the 2025 Remuneration Report and AGM Notice, as this update did not provide those details.

Implications of the July 2026 Share Issuance for IDX’s Executive Incentive Timeline

The timing of this conversion—effective 1 July 2026, likely the start of Integral Diagnostics’ new financial year—may be significant from a remuneration cycle standpoint. Many Australian companies align performance rights vesting with financial year boundaries to link incentive outcomes directly to full-year financial or operational results. The 1 July 2026 date suggests an assessment period ending 30 June 2026, although the company did not explicitly confirm this.

For investors evaluating Integral Diagnostics’ governance, this conversion highlights the presence of active multi-year executive incentive programs tied to the company’s post-merger integration. Upcoming milestones to watch include additional vesting announcements for the remaining 505,553 IDXAF STI performance rights and 2,444,653 IDXAA LTI performance rights, as well as any disclosures on further Capital Merger Performance Incentive stages in future annual reports or AGM materials.

Integral Diagnostics’ Role in Australian Diagnostic Imaging and Relevance for Shareholders

Integral Diagnostics ranks among Australia’s largest diagnostic imaging providers, operating radiology clinics across several states and in New Zealand. The company has expanded substantially through acquisitions, with the Capital Merger referenced in the performance incentive forming part of this growth strategy. As a healthcare infrastructure Business, Integral Diagnostics operates in a sector characterised by Recurring Revenue streams, regulatory oversight, and demand driven by population growth and ageing demographics.

The immediate share price impact of this update was not evident from publicly available information, as executive share vesting of this magnitude is generally routine corporate housekeeping rather than material news. Nonetheless, shareholders and potential investors in IDX may wish to review the company’s 2025 Remuneration Report and forthcoming FY2026 financial results to understand the broader performance context surrounding this Stage 2 vesting. The next major investor event is expected to be the annual financial results release, which will provide a comprehensive view of the group’s operational and financial performance for the period.